quadracel
pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 15 lf u; pertactin 3ug; pertussis filamentous haemagglutinin 20ug; pertussis fimbriae 2+3 5ug; pertussis toxoid, adsorbed 20ug; polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (m e f 1); polio virus type 3 32 dagu (saukett); tetanus toxoid, adsorbed 5 lf u - suspension for injection - active: diphtheria toxoid, adsorbed 15 lf u pertactin 3ug pertussis filamentous haemagglutinin 20ug pertussis fimbriae 2+3 5ug pertussis toxoid, adsorbed 20ug polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (m e f 1) polio virus type 3 32 dagu (saukett) tetanus toxoid, adsorbed 5 lf u excipient: aluminium phosphate formaldehyde glutaral neomycin phenoxyethanol polymyxin b polysorbate 80 water for injection - quadracel is indicated for primary immunisation of children from the age of 2 months to 12 months against diphtheria, tetanus, pertussis and poliomyelitis. quadracel is also indicated for the fourth dose for children from 15 months to six years of age who have been immunised previously with three doses of diphtheria, tetanus, pertussis and polio vaccines.
adacel® suspension for injection
sanofi-aventis singapore pte. ltd. - (acellular pertussis) filamentous haemagglutinin adsorbed (fha); (acellular pertussis) fimbriae type 2 and 3 adsorbed (fim); (acellular pertussis) pertactin adsorbed (prn); (acelullar pertussis) pertussis toxoid adsorbed (pt); diphtheria toxoid adsorbed; tetanus toxoid adsorbed - injection, suspension - 5 micrograms - (acellular pertussis) filamentous haemagglutinin adsorbed (fha) 5 micrograms; (acellular pertussis) fimbriae type 2 and 3 adsorbed (fim) 5 micrograms; (acellular pertussis) pertactin adsorbed (prn) 3 micrograms; (acelullar pertussis) pertussis toxoid adsorbed (pt) 2.5 micrograms; diphtheria toxoid adsorbed 2 lf; tetanus toxoid adsorbed 5 lf
adacel-polio suspension
sanofi pasteur limited - filamentous haemagglutinin; pertussis toxoid; pertactin; tetanus toxoid; fimbriae types 2 and 3 (fim); poliovirus type 1 mahoney (inactivated); poliovirus type 2 mef1 (inactivated); poliovirus type 3 saukett (inactivated); diphtheria toxoid - suspension - 5mcg; 2.5mcg; 3mcg; 5lf; 5mcg; 29unit; 7unit; 26unit; 2lf - filamentous haemagglutinin 5mcg; pertussis toxoid 2.5mcg; pertactin 3mcg; tetanus toxoid 5lf; fimbriae types 2 and 3 (fim) 5mcg; poliovirus type 1 mahoney (inactivated) 29unit; poliovirus type 2 mef1 (inactivated) 7unit; poliovirus type 3 saukett (inactivated) 26unit; diphtheria toxoid 2lf - vaccines
triaxis suspension for injection
sanofi pasteur msd ltd - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin (prn), fimbriae types 2 and 3 - suspension for injection - pertussis, purified antigen, combinations with toxoids
adacel polio
sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - suspension for injection - fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses; tetanus toxoid 5 lf / 1 doses; inactivated polio virus (ipv) type 1 40 du/dose; inactivated polio virus (ipv) type 2 8 du/dose; inactivated polio virus (ipv) type 3 32 du/dose - diphtheria-pertussis-poliomyelitis-tetanus - diphtheria-pertussis-poliomyelitis-tetanus - active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 4 years and over as a booster following primary immunisation.adacel polio is not indicated for primary immunisation. adacel polio is not indicated for treating diseases caused by b.pertussis, c.diphtheriae or c.tetani or by poliomyelitis infections
adacel
sanofi-aventis australia pty ltd - pertussis fimbriae 2 + 3; pertussis filamentous haemagglutinin; tetanus toxoid; diphtheria toxoid; pertactin; pertussis toxoid -
boostrix preservative free
glaxosmithkline australia pty ltd - diphtheria toxoid; pertactin; tetanus toxoid; pertussis filamentous haemagglutinin; pertussis toxoid -
infanrix - ipv
glaxosmithkline australia pty ltd - pertussis filamentous haemagglutinin; pertactin; pertussis toxoid; tetanus toxoid; poliovirus; diphtheria toxoid -
repevax %v/v suspension for injection
sanofi pasteur msd ltd - tetanus toxoid diphtheria toxoid pertussis toxoid filamentous haemagglutinin (fha) pertactin polio virus type 1 inactivated polio virus type 2 inactivated polio virus type 3 inactivated adsorbed fimbriae types 2 + 3 - suspension for injection - %v/v
quadracel 0.5ml injection vial
sanofi-aventis australia pty ltd - tetanus toxoid, quantity: 40 iu; pertussis fimbriae 2 + 3, quantity: 5 microgram; diphtheria toxoid, quantity: 30 iu; poliovirus, quantity: 29 dagu; poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertussis toxoid, quantity: 20 microgram; pertactin, quantity: 3 microgram; pertussis filamentous haemagglutinin, quantity: 20 microgram - injection, suspension - excipient ingredients: polymyxin b sulfate; bovine serum albumin; formaldehyde; phenoxyethanol; glutaral; neomycin; water for injections; polysorbate 80; aluminium phosphate - quadracel is indicated for primary immunisation of children from the age of 2 months to 12 months against diphtheria, tetanus, pertussis, and poliomyelitis.,quadracel is also indicated for the fourth dose for children from 15 months to six years of age who have been immunised previously with three doses of diphtheria, tetanus, pertussis and polio vaccines.